BioWorld

Sep. 25, 2007

View Archived Issues

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today) Read More

Celgene Paying Array $40M Up Front For Drug Discovery

Read More

Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus

Read More

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Read More

Elixir Aiming For Public Markets With $86M IPO

Read More

Other News To Note

Read More

Clinic Roundup

Read More